Shots:
Mabwell has dosed the first patient with 7MW4911 in a P-Â I/II study in the US for the treatment of advanced colorectal cancer & other advanced GI tumors
Preclinical studies showed that 7MW4911 delivered potent antitumor activity across CDX/PDX GI tumor models & outperformed MMAE/DXd-based ADCs in multidrug-resistant settings. It also reversed tumor progression after…
